Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece

AIM: The aim of the present study was to estimate the annual per-patient cost of treatment with adalimumab, etanercept, infliximab, and ustekinumab by response status for new and existing patients with moderate to severe psoriasis in Greece. METHODS: An economic analysis was developed from a nationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoulakis, Vassilis, Raptis, Efklidis, Vitsou, Elli, Maniadakis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293299/
https://www.ncbi.nlm.nih.gov/pubmed/25609988
http://dx.doi.org/10.2147/CEOR.S75263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293299/
https://www.ncbi.nlm.nih.gov/pubmed/25609988
http://dx.doi.org/10.2147/CEOR.S75263

Ejemplares similares